This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Regeneron (REGN) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Regeneron (REGN) delivered earnings and revenue surprises of 28.29% and 7.74%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Eli Lilly (LLY) Q4 Earnings Miss, COVID Therapies Aid Sales
by Zacks Equity Research
Eli Lilly (LLY) misses earnings estimates in the fourth quarter while revenues beat the same. Stock down in pre-market trading.
Roche's (RHHBY) 2021 Earnings, Sales Grow on COVID-19 Tests
by Zacks Equity Research
Roche (RHHBY) performance in the fourth quarter and 2021 was encouraging, driven by demand for COVID-19 tests and recovery in pharma sales. However, sales are expected to slow down in 2022.
Why Regeneron (REGN) Might Surprise This Earnings Season
by Zacks Equity Research
Regeneron (REGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Drug/Biotech Stock Q4 Earnings Due on Feb 4: BMY, REGN & SNY
by Sundeep Ganoria
Let us take a look at three biotech/pharma companies ¿¿¿ BMY, REGN and SNY ¿¿¿ that are slated to release quarterly results on Feb 4.
Biotech Stock Roundup: GILD Q4 Earnings, REGN, MRNA's Regulatory Updates & More
by Zacks Equity Research
Earnings updates from Gilead (GILD) and regulatory updates are among a few key highlights from the biotech sector during the past week.
Zacks Industry Outlook Highlights: Regeneron, Vertex Pharmaceuticals, Dynavax Technologies Corp. and Repligen
by Zacks Equity Research
Regeneron, Vertex Pharmaceuticals, Dynavax Technologies Corp. and Repligen are highlighted in this Industry Outlook article.
Eli Lilly (LLY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) fourth-quarter sales.
4 Top Biotech Stocks to Gain Amid Industry Challenges
by Ekta Bagri
New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position VRTX, REGN, DVAX and RGEN well amid the volatility.
Regeneron (REGN) Withdraws sBLA for Libtayo in Cervical Cancer
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi voluntarily withdraw the supplemental biologics license application for Libtayo in second-line treatment of advanced cervical cancer.
Will Eylea, Dupixent Aid Regeneron's (REGN) Q4 Earnings?
by Zacks Equity Research
Regeneron's (REGN) fourth-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent and incremental contribution from its antibody cocktail.
Regeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen (BIIB) to Sell Biosimilar JV Stake to Samsung Biologics
by Zacks Equity Research
Biogen (BIIB) is selling its equity stake in the Samsung Bioepis joint venture to partner Samsung Biologics
The Zacks Analyst Blog Highlights: Eli Lilly, Regeneron Pharmaceuticals, Pfizer and Merck
by Zacks Equity Research
Eli Lilly, Regeneron Pharmaceuticals, Pfizer and Merck are included in this blog.
The Zacks Analyst Blog Highlights: Pfizer, Merck, Eli Lilly, Regeneron and Gilead
by Zacks Equity Research
Pfizer, Merck, Eli Lilly, Regeneron and Gilead are included in this analyst blog.
SAB Biotherapeutics (SABS) Posts Data From COVID Treatment Study
by Zacks Equity Research
Following positive data from phase II study, SAB Biotherapeutics (SABS) starts a phase III study evaluating its COVID antibody treatment.
FDA Limits Use of Regeneron & Lilly's COVID Antibody Cocktails
by Zacks Equity Research
The FDA modifies EUA for COVID-19 antibody cocktail drugs of Regeneron (REGN) and Lilly (LLY), limiting their use to treat individuals with COVID-19 infection from non-Omicron variants.
Large Cap Pharma, Biotech Stocks Down on Regulatory Updates
by Zacks Equity Research
Pharma giants like Pfizer (PFE), Merck (MRK) and Eli Lilly (LLY), along with biotech bigwig Regeneron (REGN), are down on regulatory updates.
ASLAN (ASLN) Starts Phase IIb Study in Atopic Dermatitis
by Zacks Equity Research
ASLAN (ASLN) screens the first patient in the phase II dose ranging study evaluating its investigational monoclonal antibody in patients with atopic dermatitis.
Regeneron (REGN) Rides on Solid Product Portfolio: Should You Buy?
by Zacks Equity Research
Regeneron (REGN) is expected to maintain momentum on the back of a solid and diverse portfolio. The promising pipeline also sets the stage for further growth.
Sanofi (SNY) 2nd Dupixent Prurigo Nodularis Study Meets Goal (Revised)
by Zacks Equity Research
Sanofi's (SNY) PRIME is the second successful study on Dupixent for the prurigo nodularis indication.
Biotech Stock Roundup: ZGNX's Acquisition News, REGN, BLUE's Updates & More
by Zacks Equity Research
Regulatory and other pipeline updates from Zogenix (ZGNX) and Regeneron (REGN) are among a few key highlights from the biotech sector during the past week.
Regeneron (REGN)/Sanofi's Libtayo sBLA Accepted by the FDA
by Zacks Equity Research
Regeneron (REGN) sBLA seeking label expansion of Libtayo in combination with chemotherapy as first-line treatment in advanced lung cancer accepted by the FDA.
Gamida (GMDA) Up on Omidubicel BLA Rolling Submission Plan
by Zacks Equity Research
The FDA agrees to the initiation of rolling submission of Gamida's (GMDA) BLA for its lead blood cancer candidate, omidubicel. The stock rises more than 22% on in response.